Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C5H11NO2S |
Molecular Weight | 149.211 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CSCC[C@H](N)C(O)=O
InChI
InChIKey=FFEARJCKVFRZRR-BYPYZUCNSA-N
InChI=1S/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1
Molecular Formula | C5H11NO2S |
Molecular Weight | 149.211 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugs.com/cdi/me-500.htmlCurator's Comment: description was created based on several sources, including
https://www.drugs.com/cdi/methionine.html | http://www.rxlist.info/cons/me-500.html | https://www.ncbi.nlm.nih.gov/pubmed/5124307 | https://www.ncbi.nlm.nih.gov/pubmed/14505437
Sources: https://www.drugs.com/cdi/me-500.html
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/cdi/methionine.html | http://www.rxlist.info/cons/me-500.html | https://www.ncbi.nlm.nih.gov/pubmed/5124307 | https://www.ncbi.nlm.nih.gov/pubmed/14505437
Methionine is an non-polar, aliphatic, essential α-amino acid that is used in the biosynthesis of proteins. High levels of methionine can be found in eggs, sesame seeds, Brazil nuts, fish, meats and some other plant seeds; methionine is also found in cereal grains. Most fruits and vegetables contain very little of it. Most legumes are also low in methionine. However, it is the combination of methionine and cystine which is considered for completeness of a protein. There is scientific evidence that restricting methionine consumption can increase lifespans in some animals. However, since methionine is an essential amino acid, it cannot be entirely removed from animals' diets without disease or death occurring over time. For example, rats fed a diet without methionine developed steatohepatitis (fatty liver), anemia and lost two thirds of their body weight over 5 weeks. Administration of methionine ameliorated the pathological consequences of methionine deprivation.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2111450 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3755757 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ndrugs.com/?s=meonine |
Primary | MEONINE Approved UseIt is used to make the urine more acidic. Making the urine more acidic helps to relieve skin irritation in incontinent (loss of bladder control) adults and diaper rash in infants. This medicine also helps to control strong urine odor. |
||
Primary | Me-500 Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30873855/ |
40 mg/kg single, oral dose: 40 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
METHIONINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
17.81 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30873855/ |
40 mg/kg single, oral dose: 40 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
METHIONINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.36 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30873855/ |
40 mg/kg single, oral dose: 40 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
METHIONINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
3 g 2 times / day multiple, oral Studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, 31-62 |
Disc. AE: Gastrointestinal symptom NOS... AEs leading to discontinuation/dose reduction: Gastrointestinal symptom NOS (8.3%) Sources: |
3 g 2 times / day multiple, oral Studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, 42.5 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Gastrointestinal symptom NOS | 8.3% Disc. AE |
3 g 2 times / day multiple, oral Studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, 31-62 |
PubMed
Title | Date | PubMed |
---|---|---|
Palladium(II) and platinum(II) complexes as synthetic peptidases. | 2001 |
|
Novel mutations in the GALK1 gene in patients with galactokinase deficiency. | 2001 |
|
Different usage of the glycosaminoglycan attachment sites of biglycan. | 2001 Apr 20 |
|
Saccharomyces cerevisiae is capable of de Novo pantothenic acid biosynthesis involving a novel pathway of beta-alanine production from spermine. | 2001 Apr 6 |
|
Bus, a bushy Arabidopsis CYP79F1 knockout mutant with abolished synthesis of short-chain aliphatic glucosinolates. | 2001 Feb |
|
The folate cycle and disease in humans. | 2001 Feb |
|
In situ kinetic characterization of methylthioadenosine transport by the adenosine transporter (P2) of the African Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense. | 2001 Feb 15 |
|
Regulation of cell function by methionine oxidation and reduction. | 2001 Feb 15 |
|
Trp 346 and Leu 352 residues in protective antigen are required for the expression of anthrax lethal toxin activity. | 2001 Feb 16 |
|
Extracellular amino acid profiles in the paraventricular nucleus of the rat hypothalamus are influenced by diet composition. | 2001 Feb 23 |
|
Orientations of Tyr 21 and Tyr 24 in the capsid of filamentous virus Ff determined by polarized Raman spectroscopy. | 2001 Feb 6 |
|
Intestinal disappearance and mesenteric and portal appearance of amino acids in dairy cows fed ruminally protected methionine. | 2001 Jan |
|
Intestinal apical amino acid absorption during development of the pig. | 2001 Jan |
|
Intestinal aminooligopeptidase in diabetic BioBreed rat: altered posttranslational processing and trafficking. | 2001 Jan |
|
Characterization of promoter region and genomic structure of the murine and human genes encoding Src like adapter protein. | 2001 Jan 10 |
|
Cloning and functional analysis of the Sry-related HMG box gene, Sox18. | 2001 Jan 10 |
|
Analysis of the subsite specificity of rat insulysin using fluorogenic peptide substrates. | 2001 Jan 12 |
|
Selective degradation of oxidized calmodulin by the 20 S proteasome. | 2001 Jan 12 |
|
Sec63p and Kar2p are required for the translocation of SRP-dependent precursors into the yeast endoplasmic reticulum in vivo. | 2001 Jan 15 |
|
Haem-linked interactions in horseradish peroxidase revealed by spectroscopic analysis of the Phe-221-->Met mutant. | 2001 Jan 15 |
|
Thromboangiitis obliterans (Buerger's disease). | 2001 Jan 18 |
|
Diet-induced hyperhomocysteinemia exacerbates neointima formation in rat carotid arteries after balloon injury. | 2001 Jan 2 |
|
Comparison of Vif sequences from diverse geographical isolates of HIV type 1 and SIV(cpz) identifies substitutions common to subtype C isolates and extensive variation in a proposed nuclear transport inhibition signal. | 2001 Jan 20 |
|
Electronic characterization of the oxidized state of the blue copper protein rusticyanin by 1H NMR: is the axial methionine the dominant influence for the high redox potential? | 2001 Jan 23 |
|
Mapping the energy surface for the folding reaction of the coiled-coil peptide GCN4-p1. | 2001 Jan 23 |
|
The additional methionine residue at the N-terminus of bacterially expressed human interleukin-2 affects the interaction between the N- and C-termini. | 2001 Jan 30 |
|
Crystallization and preliminary X-ray crystallographic studies of recombinant human betaine-homocysteine S-methyltransferase. | 2001 Mar |
|
The effects of oral methionine and homocysteine on endothelial function. | 2001 Mar |
|
Evidence against oxidative stress as mechanism of endothelial dysfunction in methionine loading model. | 2001 Mar |
|
Relative reactivities of N-chloramines and hypochlorous acid with human plasma constituents. | 2001 Mar 1 |
|
COMT-dependent protection of dopaminergic neurons by methionine, dimethionine and S-adenosylmethionine (SAM) against L-dopa toxicity in vitro. | 2001 Mar 2 |
|
Impaired ATP synthase assembly associated with a mutation in the human ATP synthase subunit 6 gene. | 2001 Mar 2 |
|
Transporters on demand: intrahepatic pools of canalicular ATP binding cassette transporters in rat liver. | 2001 Mar 9 |
|
Sequence requirements for the N-methyl-D-aspartate receptor antagonist activity of conantokin-R. | 2001 Mar 9 |
|
Uptake of tritiated thymidine, deoxyglucose and methionine in three lung cancer cell lines: deoxyglucose uptake mirrors tritiated thymidine uptake. | 2001 Mar-Apr |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/cons/me-500.html
Adults and teenagers—The usual dose is 200 milligrams (mg) three or four times a day.
Children—The usual dose is the contents of 1 capsule (200 mg) added to a warm bottle of milk or formula in the evening, or added to a glass of juice or water.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14505437
MCF-7 cells were obtained from American Type Culture Collection (Manassas, VA). Cells were cultured in a 5% CO~-humidified atmosphere at 37 OC in control medium, which consisted of Dulbecco's modified Eagle medium-F12 medium (1:1) supplemented with 5% bovine serum and 10 txg/ml insulin. Various concentrations (0.02, 0.2, 2, 5, and 10 g of methionine/L) were tested to determine the optimal level of methionine supplementation that causes the maximum inhibition of breast cancer cells. Cells were seeded in 96-well plates at a density of 1 • 10 a cells/well and grown in control medium for 24 h. The medium was then replaced with either control or methionine-supplemented treatment media as described above. Cell growth was assessed daily by the CellTiter 96 Aqueous One-Solution Cell Proliferation Assay reagent (Promega, Madison, WI). We found that cell growth was significantly suppressed by 5 to 10 g/L methionine on day 1, and no more growth was detected after 3 d of treatment.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:17:41 GMT 2025
by
admin
on
Mon Mar 31 18:17:41 GMT 2025
|
Record UNII |
AE28F7PNPL
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
47706-7
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
63380-0
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
56957-4
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
53397-6
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
53156-6
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
26963-9
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
17264-3
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
DSLD |
171 (Number of products:32)
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
25959-8
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
47702-6
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
47701-8
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
DSLD |
1779 (Number of products:2)
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
WHO-ATC |
V03AB26
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
DSLD |
2065 (Number of products:1257)
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
27098-3
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
WHO-VATC |
QG04BA90
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
44338-2
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
2624-5
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
47703-4
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
15130-8
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
26844-1
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
FDA ORPHAN DRUG |
91795
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
47700-0
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
25956-4
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
47704-2
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
22681-1
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
15145-6
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
NCI_THESAURUS |
C68442
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
2622-9
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
13405-6
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
WHO-VATC |
QV03AB26
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
20651-6
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
13772-9
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
47705-9
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
53161-6
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
2621-1
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
55943-5
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
CFR |
21 CFR 172.320
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
WHO-VATC |
QA05BA90
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
32258-6
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
30063-2
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
13376-9
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
22716-5
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
27953-9
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
2623-7
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
25476-3
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
2620-3
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
32257-8
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
||
|
LOINC |
22648-0
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
22946
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
49038
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
AE28F7PNPL
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
64558
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
DB00134
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
SUB21984
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
452
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
D008715
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
49037
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
6837
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | RxNorm | ||
|
1411504
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
16044
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
16811
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
SUB08850MIG
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
m7317
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | Merck Index | ||
|
63-68-3
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
C29600
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
3347
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
CHEMBL42336
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
200-562-9
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
4317
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
57844
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
CHEMBL274119
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
AE28F7PNPL
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
DTXSID5040548
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
100000092414
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
METHIONINE
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
6137
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY | |||
|
16643
Created by
admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
LABELED -> NON-LABELED | |||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
EP
|
||
|
IMPURITY -> PARENT |
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
IMPURITY -> PARENT |
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|